Literature DB >> 33737947

Comprehensive Analysis of Survival-Related lncRNAs, miRNAs, and mRNAs Forming a Competing Endogenous RNA Network in Gastric Cancer.

Yanjie Zhao1, Heng Zhang1, Qiang Ju2, Xinmei Li1, Yuxin Zheng1.   

Abstract

To analyze and construct a survival-related endogenous RNA (ceRNA) network in gastric cancer (GC) with lymph node metastasis, we obtained expression profiles of long non-coding RNAs (lncRNAs), mRNAs, and microRNAs (miRNAs) in GC from The Cancer Genome Atlas database. The edgeR package was used to screen differentially expressed lncRNAs, mRNAs, and miRNAs between GC patients with lymphatic metastasis and those without lymphatic metastasis. Then, we used univariate Cox regression analysis to identify survival-related differentially expressed RNAs. In addition, we used multivariate Cox regression analysis to screen lncRNAs, miRNAs, and mRNAs for use in the prognostic prediction models. The results showed that 2,247 lncRNAs, 155 miRNAs, and 1,253 mRNAs were differentially expressed between the two patient groups. Using univariate Cox regression analysis, we found that 395 lncRNAs, eight miRNAs, and 180 mRNAs were significantly related to the survival time of GC patients. We next created a survival-related network consisting of 59 lncRNAs, seven miRNAs, and 36 mRNAs. In addition, we identified eight RNAs associated with prognosis by multivariate Cox regression analysis, comprising three lncRNAs (AC094104.2, AC010457.1, and AC091832.1), two miRNAs (miR-653-5p and miR-3923), and three mRNAs (C5orf46, EPHA8, and HPR); these were used to construct the prognostic prediction models, and their risk scores could be used to assess GC patients' prognosis. In conclusion, this study provides new insights into ceRNA networks in GC and the screening of prognostic biomarkers for GC.
Copyright © 2021 Zhao, Zhang, Ju, Li and Zheng.

Entities:  

Keywords:  ceRNA; gastric cancer; lncRNA; mRNA; miRNA; prognosis

Year:  2021        PMID: 33737947      PMCID: PMC7960915          DOI: 10.3389/fgene.2021.610501

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


  7 in total

1.  Analysis of PANoptosis-Related LncRNA-miRNA-mRNA Network Reveals LncRNA SNHG7 Involved in Chemo-Resistance in Colon Adenocarcinoma.

Authors:  Jingjing Huang; Shiyao Jiang; Lu Liang; Hua He; Yueying Liu; Li Cong; Yiqun Jiang
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

2.  Pan-Cancer Analysis Reveals FH as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma.

Authors:  Heng Zhang; Qiang Ju; Jing Ji; Yanjie Zhao
Journal:  Dis Markers       Date:  2021-10-26       Impact factor: 3.434

3.  N6-Methyladenosine Methylation Regulator RBM15 is a Potential Prognostic Biomarker and Promotes Cell Proliferation in Pancreatic Adenocarcinoma.

Authors:  Zhiying Zhao; Qiang Ju; Jing Ji; Yutong Li; Yanjie Zhao
Journal:  Front Mol Biosci       Date:  2022-02-09

4.  Profiling and Integrated Analysis of Differentially Expressed MicroRNAs as Novel Biomarkers of Hepatocellular Carcinoma.

Authors:  Yuwei Xie; Yixiu Wang; Weijie Xue; Hao Zou; Kun Li; Kui Liu; Wei Zhao; Chengzhan Zhu; Jingyu Cao
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

5.  Preliminary study on the role of the C5orf46 gene in renal cancer.

Authors:  Ming Ma; Zhicheng Zhang; Yifu Liu; Zhilong Li; Shengqiang Fu; Qiang Chen; Siyuan Wang
Journal:  Transl Oncol       Date:  2022-04-30       Impact factor: 4.803

6.  Identification of Key Circulating Exosomal microRNAs in Gastric Cancer.

Authors:  Xiaoqing Qian; Feng Xie; Huabing Wei; Daxiang Cui
Journal:  Front Oncol       Date:  2021-07-16       Impact factor: 6.244

7.  The Role of miR-4256/HOXC8 Signaling Axis in the Gastric Cancer Progression: Evidence From lncRNA-miRNA-mRNA Network Analysis.

Authors:  Haijuan Gu; Yuejiao Zhong; Jibin Liu; Qian Shen; Rong Wei; Haixia Zhu; Xunlei Zhang; Xianxian Xia; Min Yao; Meixin Ni
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.